Dendreon Corp fka DNDNQ

[walldiver]

Investor 760, while I disagree strongly with Dew on DNDN's prospects, I welcome skeptical posts about the company as long as they don't deviate from important facts and they DON'T attack people personally. Much about biotech investing is trying to read between the lines of public statements by the company in question. Dew has a different take on DNDN's situation than the DNDN longs do. So does one of the smartest biopharma investors I've ever seen, a person who knows more about the subject than just about every biotech analyst and Phd combined.

We don't want to start off on the wrong foot on this new board and impugn the motives of intelligent skeptics. When Dew says he has no position in DNDN, long or short, I believe him...especially because he makes no secret about which companies he is currently shorting, LOL.

Given such a large short position in the stock and its current low market cap, DNDN is a coiled spring. Dew knows that positive FDA news (step 1 acceptance of BLA, step 2 not overly negative briefing docs, step 3 thumbs up panel reco) would set that spring off.

If we were in a biotech bull market or if DNDN had waited until January to do its secondary, the stock price would be higher. It goes without saying that the price would be different if the company weren't a favorite whipping boy of the hedge funds.